See more : Chubu Steel Plate Co., Ltd. (5461.T) Income Statement Analysis – Financial Results
Complete financial analysis of Imunon, Inc. (CLSN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Imunon, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Goodrich Petroleum Corporation (GDP) Income Statement Analysis – Financial Results
- Westmount Energy Limited (WMELF) Income Statement Analysis – Financial Results
- CTS Co., Ltd. (4345.T) Income Statement Analysis – Financial Results
- PT Sinar Mas Agro Resources and Technology Tbk (SMAR.JK) Income Statement Analysis – Financial Results
- The Music Acquisition Corporati (TMAC-WT) Income Statement Analysis – Financial Results
Imunon, Inc. (CLSN)
About Imunon, Inc.
Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 500.00K | 0.00 | 2.00M | 0.00 | 0.00 | 2.50M | 0.00 | 11.25M | 12.32M | 2.51M | 0.00 | 0.00 | 0.00 | 3.42K | 100.00K | 174.18K | 121.26K | 74.01K |
| Cost of Revenue | 720.01K | 731.63K | 702.92K | 11.34M | 13.07M | 11.07M | 13.08M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.67M | 8.11M | 2.10M | 0.00 | 0.00 | 0.00 | -39.23K | 0.00 | 136.50K | 46.73K | 64.41K |
| Gross Profit | -720.01K | -231.63K | -202.92K | -10.84M | -12.57M | -10.57M | -12.58M | 500.00K | 500.00K | 500.00K | 500.00K | 0.00 | 2.00M | 0.00 | 0.00 | 2.50M | 0.00 | 4.58M | 4.21M | 405.34K | 0.00 | 0.00 | 0.00 | 42.65K | 100.00K | 37.68K | 74.52K | 9.60K |
| Gross Profit Ratio | 0.00% | -46.33% | -40.58% | -2,168.96% | -2,513.06% | -2,113.10% | -2,515.74% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 40.72% | 34.15% | 16.17% | 0.00% | 0.00% | 0.00% | 1,247.13% | 100.00% | 21.63% | 61.46% | 12.97% |
| Research & Development | 11.29M | 11.73M | 10.62M | 11.34M | 13.07M | 11.87M | 13.08M | 14.62M | 14.66M | 14.97M | 9.36M | 15.77M | 19.86M | 14.71M | 13.68M | 12.01M | 8.23M | 9.35M | 10.08M | 11.53M | 8.18M | 5.00M | 4.08M | 2.24M | 1.00M | 1.53M | 185.97K | 94.01K |
| General & Administrative | 9.74M | 13.69M | 10.89M | 7.64M | 8.00M | 9.70M | 5.89M | 6.53M | 6.69M | 8.86M | 6.55M | 6.37M | 0.00 | 4.92M | 3.33M | 2.04M | 5.35M | 3.72M | 3.41M | 0.00 | 0.00 | 4.83M | 3.21M | 2.66M | 1.40M | 2.52M | 2.28M | 1.34M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 390.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.74M | 13.69M | 10.89M | 7.64M | 8.00M | 9.70M | 5.89M | 6.53M | 6.69M | 8.86M | 6.55M | 6.37M | 5.15M | 4.92M | 3.33M | 2.04M | 5.35M | 3.72M | 3.41M | 3.47M | 5.13M | 4.83M | 3.21M | 2.66M | 1.40M | 2.52M | 2.28M | 1.34M |
| Other Expenses | 0.00 | 5.40M | 1.62M | -1.30M | 3.19M | 3.63M | 651.97K | 733.00K | -259.45K | 265.89K | -2.53K | -1.04K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.01M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 39.48K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.03M | 25.42M | 21.51M | 18.99M | 21.07M | 21.57M | 18.97M | 21.15M | 21.35M | 23.83M | 15.91M | 22.14M | 25.02M | 19.64M | 17.01M | 14.05M | 13.59M | 14.08M | 13.49M | 15.00M | 13.30M | 9.84M | 7.29M | 4.94M | 2.40M | 4.05M | 2.47M | 1.43M |
| Cost & Expenses | 21.03M | 25.42M | 21.51M | 18.99M | 21.07M | 21.57M | 18.97M | 21.15M | 21.35M | 23.83M | 15.91M | 22.14M | 25.02M | 19.64M | 17.01M | 14.05M | 13.59M | 20.75M | 21.60M | 17.11M | 13.30M | 9.84M | 7.29M | 4.90M | 2.40M | 4.19M | 2.52M | 1.50M |
| Interest Income | 960.55K | 502.58K | 18.15K | 66.55K | 442.99K | 331.78K | 26.04K | 31.26K | 186.32K | 1.02M | 748.95K | 0.00 | 174.06K | 32.29K | 46.16K | 221.71K | 0.00 | 636.56K | 299.25K | 0.00 | 30.38K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 4.57M | 557.00K | 1.29M | 1.39M | 712.03K | 91.76K | 693.00K | 1.36M | 1.33M | 915.24K | 307.00K | 501.86K | 31.52K | 94.92K | 141.61K | 49.42M | 1.10M | 179.59K | 0.00 | -13.27M | -9.75M | -6.92M | 0.00 | 0.00 | 199.35K | 0.00 | 85.51K |
| Depreciation & Amortization | 720.01K | 731.63K | 702.92K | 741.52K | 721.67K | 356.86K | 553.01K | 1.03M | 424.97K | 369.33K | 339.23K | 281.49K | 176.86K | 172.98K | 109.65K | 69.47K | -39.11K | -341.29K | -321.39K | -275.68K | 100.53K | 82.44K | 68.85K | 39.48K | -100.00K | 24.29K | 24.17K | 18.55K |
| EBITDA | -19.88M | -31.71M | -20.88M | -21.30M | -16.55M | -21.23M | -19.76M | -20.30M | -20.67M | -23.79M | -6.99M | -25.92M | -22.54M | -18.61M | -15.80M | -11.58M | -13.13M | -9.84M | -9.50M | -14.78M | -13.20M | -9.79M | -7.26M | -4.86M | -2.40M | -3.99M | -2.37M | -1.40M |
| EBITDA Ratio | 0.00% | -3,905.20% | -3,877.00% | -3,795.72% | -3,242.17% | -3,349.10% | -3,447.48% | -3,983.40% | -4,098.99% | -4,335.91% | -2,865.17% | 0.00% | -1,133.39% | 0.00% | 0.00% | -463.01% | 0.00% | -94.55% | -77.14% | -589.83% | 0.00% | 0.00% | 0.00% | -142,016.75% | -2,300.00% | -2,296.79% | -1,960.88% | -1,936.39% |
| Operating Income | -21.03M | -24.92M | -21.01M | -18.49M | -20.57M | -21.07M | -18.47M | -20.65M | -20.85M | -24.72M | -15.41M | -22.14M | -23.02M | -19.64M | -17.01M | -11.55M | -13.59M | -8.49M | -9.28M | -14.60M | -13.30M | -9.84M | -7.29M | -4.90M | -2.30M | -4.01M | -2.39M | -1.42M |
| Operating Income Ratio | 0.00% | -4,984.40% | -4,201.40% | -3,697.28% | -4,113.09% | -4,213.01% | -3,693.69% | -4,130.00% | -4,169.36% | -4,943.04% | -3,082.30% | 0.00% | -1,150.94% | 0.00% | 0.00% | -461.98% | 0.00% | -75.43% | -75.32% | -582.51% | 0.00% | 0.00% | 0.00% | -143,171.08% | -2,300.00% | -2,303.92% | -1,974.89% | -1,922.52% |
| Total Other Income/Expenses | 235.07K | -12.54M | -1.15M | -4.84M | 1.90M | -1.24M | -1.93M | -1.40M | -1.61M | -779.08K | 7.16M | -4.43M | -203.91K | 818.99K | 1.01M | -236.80K | -483.23K | 902.40K | -96.89K | 613.90K | 30.38K | 86.61K | 363.65K | 349.24K | -100.00K | -187.48K | -657.19K | -510.69K |
| Income Before Tax | -20.80M | -37.47M | -22.15M | -23.33M | -18.67M | -22.30M | -20.40M | -22.05M | -22.46M | -25.49M | -8.25M | -26.57M | -23.22M | -18.82M | -16.00M | -11.79M | -14.07M | -7.58M | -8.69M | -13.99M | -13.27M | -9.75M | -6.92M | -4.55M | -2.40M | -4.20M | -3.05M | -1.93M |
| Income Before Tax Ratio | 0.00% | -7,493.00% | -4,430.60% | -4,665.88% | -3,733.60% | -4,460.49% | -4,080.44% | -4,410.80% | -4,492.22% | -5,098.85% | -1,650.27% | 0.00% | -1,161.13% | 0.00% | 0.00% | -471.45% | 0.00% | -67.41% | -70.50% | -558.01% | 0.00% | 0.00% | 0.00% | -132,959.50% | -2,400.00% | -2,411.55% | -2,516.88% | -2,612.59% |
| Income Tax Expense | -1.28M | -1.57M | -1.38M | -1.85M | -1.82M | -10.42M | 1.93M | 1.40M | 1.61M | 779.08K | 1.00 | 4.43M | 203.91K | -818.99K | -806.00K | 236.80K | -49.42M | -1.91M | 8.69M | -613.90K | 13.27M | 9.75M | 6.92M | 4.55M | 2.40M | 187.48K | 657.19K | 510.69K |
| Net Income | -19.51M | -35.90M | -20.77M | -21.48M | -16.85M | -11.88M | -20.40M | -22.05M | -22.46M | -25.49M | -8.25M | -26.57M | -23.22M | -18.82M | -15.19M | -11.79M | 35.35M | -7.58M | -8.69M | -13.99M | -13.27M | -9.75M | -6.92M | -4.55M | -2.40M | -4.20M | -3.05M | -1.93M |
| Net Income Ratio | 0.00% | -7,179.60% | -4,153.80% | -4,296.71% | -3,370.31% | -2,376.67% | -4,080.44% | -4,410.80% | -4,492.22% | -5,098.85% | -1,650.27% | 0.00% | -1,161.13% | 0.00% | 0.00% | -471.45% | 0.00% | -67.41% | -70.50% | -558.01% | 0.00% | 0.00% | 0.00% | -132,959.50% | -2,400.00% | -2,411.55% | -2,516.88% | -2,612.59% |
| EPS | -2.16 | -5.03 | -3.60 | -10.08 | -11.58 | -10.14 | -40.12 | -178.43 | -216.24 | -289.83 | -127.97 | -721.68 | -1.05K | -1.44K | -1.35K | -1.10K | 3.11K | -668.10 | -765.29 | -1.25K | -1.66K | -1.58K | -1.36K | -1.09K | -741.20 | -105.01 | -1.52K | -1.09K |
| EPS Diluted | -2.16 | -5.03 | -3.60 | -10.08 | -11.58 | -10.14 | -40.12 | -178.42 | -216.24 | -289.83 | -127.97 | -721.68 | -1.05K | -1.44K | -1.35K | -1.10K | 2.90K | -668.10 | -760.54 | -1.25K | -1.66K | -1.58K | -1.36K | -1.09K | -741.20 | -193.97 | -1.52K | -1.09K |
| Weighted Avg Shares Out | 9.05M | 7.14M | 5.77M | 2.13M | 1.46M | 1.17M | 508.48K | 123.60K | 103.87K | 87.96K | 64.48K | 36.81K | 22.14K | 13.10K | 11.28K | 10.74K | 11.36K | 11.35K | 11.35K | 11.20K | 8.02K | 6.16K | 5.10K | 4.19K | 3.24K | 40.00K | 2.00K | 1.78K |
| Weighted Avg Shares Out (Dil) | 9.05M | 7.14M | 5.77M | 2.13M | 1.46M | 1.17M | 508.48K | 123.60K | 103.87K | 87.96K | 64.48K | 36.81K | 22.14K | 13.10K | 11.28K | 10.74K | 12.18K | 11.35K | 11.42K | 11.20K | 8.02K | 6.16K | 5.10K | 4.19K | 3.24K | 21.66K | 2.00K | 1.78K |
Celsion's Ovarian Cancer Immunotherapy Shows 38% Improvement In R0 Resection Rates Versus Control Arm
Celsion Corporation (NASDAQ: CLSN) reports interim observations and provides an update on its Phase 1/2 OVATION 2 study with GEN-1 in newly diagnosed patients with stage 3/4 ovarian cancer. GEN-1 is a DNA-mediated interleukin-12 (IL-12) immunotherapy.
Celsion Corporation Provides Clinical Update on Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer Including Encouraging Interim Resection Scores
Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement
Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years
CLSN Stock Price Increases Over 50% Pre-Market: Why It Happened
The stock price of Celsion Corporation (NASDAQ: CLSN) is trading at over 50% pre-market. This is why it happened.
Celsion Corporation Receives FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer
Celsion's Commitment to Promoting Immune System Solutions to Fight Life-Threatening Diseases Granted an Accelerated Development Pathway
Celsion Corporation Announces Formation of Vaccine Advisory Board
Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2
CLSN Stock: Why Biotech Company Celsion Is Soaring Today
Celsion (CLSN) stock is rising higher on Thursday after the release of a letter from chairman, president and CEO Michael Tardugno. The post CLSN Stock: Why Biotech Company Celsion Is Soaring Today appeared first on InvestorPlace.
CLSN Stock Price Increases Over 16% Pre-Market: Why It Happened
The stock price of Celsion Corporation (NASDAQ: CLSN) has increased by over 16% pre-market. This is why it happened.
Is the Options Market Predicting a Spike in Celsion (CLSN) Stock?
Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.
CELSION CORPORATION ANNOUNCES CLOSING OF $35 MILLION REGISTERED DIRECT OFFERING OF COMMON STOCK PRICED AT-THE-MARKET UNDER NASDAQ RULES
Lawrenceville, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced registered direct offering of 25,925,925 shares of common stock at a purchase price of $1.35...
Source: https://incomestatements.info
Category: Stock Reports